does glp 1 cause cancer Risk of pancreatic associated with GLP-1 receptor agonist therapy Glucagon-like peptide 1 receptor agonist

A meta-analysis of 25 studies of GLP-1 receptor agonists showed no increase in major adverse cardiovascular events (including cardiovascular death, nonfatal myocardial infarction, stroke, and acute coronary syndromes and/or heart failure reported as serious adverse events) versus all comparators, with a significant reduction versus placebo (odds ratio 0.506, P = 0.029) (29)

DPP-4 inhibitors prevent enhancing insulin secretion, incretin degradation, and reducing glucagon release for better glucose control 3.1

Agonists of the GLP-1 receptor have been developed to treat type 2 diabetes, and recent studies suggest that such agonists may also have important effects in the control of obesity1, 2

This occurred due to an unexpected increase in demand without adequate adjustment in production

Taking it later in the day after eating will compromise absorption and reduce its effectiveness in managing type 2 diabetes